SCHEMBL485772

SCHEMBL485772

CC(C)(C)OC(=O)N1CCN(C(=O)Cl)CC1

nearest known ligand 0.58

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.58
SMN1; SMN2 Q16637 1/20 0.58
EPHX2 P34913 1/20 0.51
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
HPGD P15428 1/20 0.49
POLB P06746 1/20 0.47
RECQL P46063 1/20 0.46
EPHX1 P07099 1/20 0.46
NR1H2 P55055 1/20 0.46
STS P08842 1/20 0.46
ALDH1A1 P00352 2/20 0.45
LMNA P02545 1/20 0.45
MAPT P10636 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL17746705 0.98 USP2 (0.56) USP2SMN1; SMN2EPHX2MEN1KMT2A
SCHEMBL698803 0.89 USP2 (0.69) USP2SMN1; SMN2EPHX2MEN1KMT2A
SCHEMBL18294 0.89 USP2 (0.69) USP2SMN1; SMN2EPHX2MEN1KMT2A
SCHEMBL28147263 0.87 USP2 (0.50) USP2SMN1; SMN2EPHX2MEN1KMT2A
SCHEMBL23257682 0.87 USP2 (0.50) USP2SMN1; SMN2EPHX2MEN1KMT2A
SCHEMBL27904352 0.84 USP2 (0.55) USP2SMN1; SMN2EPHX2MEN1KMT2A
SCHEMBL15365167 0.83 USP2 (0.58) USP2SMN1; SMN2EPHX2MEN1KMT2A
SCHEMBL10292758 0.83 USP2 (0.58) USP2SMN1; SMN2EPHX2MEN1KMT2A
SCHEMBL21184070 0.83 NR1H2 (0.48) USP2SMN1; SMN2EPHX2MEN1KMT2A
SCHEMBL16612394 0.83 USP2 (0.62) USP2SMN1; SMN2EPHX2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 351 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260116890-A1 ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS NUVATION BIO INC (US) 2026-04-30 US disclosed
US-20260102501-A1 ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS NUVATION BIO INC (US) 2026-04-16 US disclosed
EP-4691465-A2 SUBSTITUTED 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE The Trustees of Columbia University in the City of New York (US) 2026-02-11 EP disclosed
EP-4036094-B1 SUBSTITUTED 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE UNIV COLUMBIA (US) 2025-12-24 EP disclosed
US-20250320218-A1 SUBSTITUTED 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2025-10-16 US disclosed
US-12404277-B2 Substituted 4-phenylpiperidines, their preparation and use THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2025-09-02 US disclosed
US-20250262205-A1 DUAL MAGL AND FAAH INHIBITORS LUNDBECK LA JOLLA RESEARCH CENTER, INC. (US) 2025-08-21 US disclosed
EP-4593824-A2 ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS Nuvation Bio Inc. (US) 2025-08-06 EP disclosed
US-20250228835-A1 PYRIDINYLOXYPYRIDINES AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS RECTIFY PHARMACEUTICALS, INC. 2025-07-17 US disclosed
US-12344597-B2 Alkoxy-substituted pyridinyl derivatives as LPA1 receptor antagonists and their use in the treatment of fibrosis IDORSIA PHARMACEUTICALS LTD (CH) 2025-07-01 US disclosed
US-6211228-B1 COMPOUNDS WITH AMINO, GUANIDINO AND AMIDINO HETEROCYCLIC COMPOUNDS AXYS PHARMACEUTICALS, INC 2001-04-03 US disclosed
US-6117870-A USEFUL AS THERAPEUTIC DRUG OR PREVENTIVE DRUG OF ARTHRITIS AND RHEUMATISM DUE TO INCREASE OF BONE RESORPTION IN ADDITION TO BONE DISEASES SUCH AS OSTEOPOROSIS, HYPERCALCEMIA, AND PAGET'S DISEASE FUJIREBIO KABUSHIKI KAISHA (JP) 2000-09-12 US disclosed
EP-1008592-A2 Cyclic amide derivatives which inhibit cathepsin K Fujirebio Kabushiki Kaisha (JP) 2000-06-14 EP disclosed
US-6022969-A Compositions and methods for treating mast-cell mediated conditions AXYS PHARMACEUTICALS, INC. (US) 2000-02-08 US disclosed
WO-1999067215-A1 AMIDINO AND GUANIDINO AZETIDINONE TRYPTASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 1999-12-29 WO disclosed
EP-0782571-A1 COMPOSITIONS AND METHODS FOR TREATING MAST-CELL INFLAMMATORY CONDITION ARRIS PHARMACEUTICAL CORPORATION (US) 1997-07-09 EP disclosed
WO-1996009297-A1 COMPOSITIONS AND METHODS FOR TREATING MAST-CELL INFLAMMATORY CONDITION ARRIS PHARMACEUTICAL CORPORATION (US) 1996-03-28 WO disclosed
US-4327095-A TRANQUICIZERS, ANTICONVULSANTS DECONTRACTURANTS AND HYPNOGENIC AGENTS RHONE-POULENC INDUSTRIES (FR) 1982-04-27 US disclosed
US-4220646-A TRANQUILIZERS, ANTICONVULSANTS, MUSCLE RELAXANTS, HYPNOTIC AGENTS RHONE-POULENC INDUSTRIES (FR) 1980-09-02 US disclosed
US-4124711-A TRANQUILIZERS, ANTICONVULSANTS, DECONTRACTURANTS, HYPNOTIC AGENTS RHONE-POULENC INDUSTRIES (FR) 1978-11-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12404277-B2 Substituted 4-phenylpiperidines, their preparation and use HRH4, HRH3, HRH2 USP2 3533/4885SMN1; SMN2 3850/4885EPHX2 1233/4885
US-12344597-B2 Alkoxy-substituted pyridinyl derivatives as LPA1 receptor antagonists and their use in the treatment of fibrosis LPAR1, LPAR3, LPAR2 USP2 4279/4885SMN1; SMN2 3278/4885EPHX2 1127/4885
US-20260102501-A1 ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS NR5A1, NR5A2, NR3C1 USP2 3801/4885SMN1; SMN2 3659/4885EPHX2 4172/4885
US-20250262205-A1 DUAL MAGL AND FAAH INHIBITORS FAAH, FAAH2, MAG USP2 235/4885SMN1; SMN2 745/4885EPHX2 32/4885
US-20260116890-A1 ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS NR5A1, NR3C1, NCOR1 USP2 4077/4885SMN1; SMN2 4262/4885EPHX2 3726/4885
US-20250228835-A1 PYRIDINYLOXYPYRIDINES AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS P2RY6, P2RY4, PNPO USP2 3825/4885SMN1; SMN2 516/4885EPHX2 1158/4885
US-20250320218-A1 SUBSTITUTED 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE HRH4, HRH3, HRH2 USP2 3533/4885SMN1; SMN2 3850/4885EPHX2 1233/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.